Nanoform Finland Plc | Company Release | June 10, 2026 at 13:30:00 EEST
Helsinki, Finland – Manager’s transaction related to Nanoform Finland Plc’s Chairman of the Board Miguel Calado:
Nanoform Finland Oyj - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Miguel Calado
Position: Member of the Board/Deputy member
Issuer: Nanoform Finland Oyj
LEI: 743700JJO2NU8LBS1592
Notification type: INITIAL NOTIFICATION
Reference number: 160633/5/4
____________________________________________
Transaction date: 2026-06-09
Outside a trading venue
Instrument type: SHARE
ISIN: FI4000330972
Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE
Transaction details
(1): Volume: 52500 Unit price: 0 EUR
Aggregated transactions (1):
Volume: 52500 Volume weighted average price: 0 EUR
For further information, please contact:
Henri von Haartman
Director of Investor Relations
hvh@nanoform.com
+46 7686 650 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 8 588 685 70, certifiedadviser@dnbcarnegie.se. For more information, please visit www.nanoform.com.